Intra-Cellular Therapies (STU:23I) Net Issuance of Debt : €0.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Intra-Cellular Therapies Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Intra-Cellular Therapies's net issuance of debt for the three months ended in Mar. 2024 was €0.0 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Mar. 2024 was €0.0 Mil.

Intra-Cellular Therapies Net Issuance of Debt Historical Data

The historical data trend for Intra-Cellular Therapies's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Net Issuance of Debt Chart

Intra-Cellular Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Debt

Get a 7-Day Free Trial

Intra-Cellular Therapies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Issuance of Debt	Get a 7-Day Free Trial															-	-	-	-	-

Intra-Cellular Therapies Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Intra-Cellular Therapies Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Intra-Cellular Therapies (STU:23I) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (STU:23I) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

ITCI:USA ITCI:Mexico 23I:Germany

Address

430 East 29th Street, New York, NY, USA, 10016

Website

https://www.intracellulartherapies.com

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (STU:23I) Headlines

No Headlines